669713-60-4 2-((叔丁氧羰基)氨基)-5-甲基

In other experiments, mice were serially treated with recombinant CCL2 (rCCL2) (10 µg/kg/every 3 days, i.p.), Toll-like receptor 4 (TLR4) specific ligand (lipopolysaccharide (LPS) -EB Ultrapure, 2 mg/kg/every 3 days, i.p.), LPS (2 mg/kg/every 3 days, i.p.; Solarbio), TLR4 inhibitor (TAK-242, 10 mg/kg/every 3 days, i.p.) or cyclooxygenase-2 (COX-2) inhibitor (Celecoxib, 10 mg/kg/every 3929 days, intragastric administration). Polyp or tumour load was determined as the sum of the size of all colon polyps/tumours presented per mouse. 来源文献：Yang Y, Li L, Xu C, Wang Y, Wang Z, Chen M, Jiang Z, Pan J, Yang C, Li X, Song K, Yan J, Xie W, Wu X, Chen Z,